Nevertheless, there are several recent publications which demonstrate the efficacy of NRF2 activators in other neurodegenerative diseases such as ADs, Parkinson’s disease and ALS disease (Jazwa et al., 2011; Kanno et al., 2012; Ahuja et al., 2016; Liu et al., 2016). Here, NFE2L2 is linked to Parkinson disease.